A 52-year-old woman was referred to our hospital for treatment of urachal cancer. She complained of supurapubic dull pain and gross hematuria. Computed tomography and magnetic resonance imaging showed a non-papillary sessile tumor, which was located on the dome of the bladder and invaded the small intestine. The tumor was diagnosed as Sheldon's stage IIIC urachal cancer. After three courses of neoadjuvant chemotherapy with FOLFOX4 (oxaliplatin, 5-FU and leukovolin), the tumor was reduced from 7 x 6 cm to 5.5 x 5 cm in size. Consequently, the patient underwent an en-bloc resection of the urachal tumor with the dome of the bladder and the parts of the ileum invaded by the tumor. One course of adjuvant chemotherapy (FOLFOX4) was performed. Surgical specimen revealed histologically well differentiated squamous carcinoma and invasion to the propria of the ileum. The surgical margins were negative for the cancer. For 1.5 years after the surgery, no local recurrence or distant metastasis has been observed.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Comprehensive analysis of targetable mutations and tumor microenvironment in urachal cancer.
NPJ Precis Oncol
January 2025
University of California, Irvine, Orange, CA, 92868, USA.
Urachal cancer, a rare malignancy, generally presents in the clinical setting with advanced stages of disease. Systemic treatment with chemotherapy is generally utilized in this setting. However, there remains a paucity of data on the effectiveness of immune checkpoint inhibitors or targeted therapies for urachal cancer.
View Article and Find Full Text PDFPrecision Oncology Approach for Urachal Carcinoma: A Clinical Case Report.
Int J Mol Sci
December 2024
Department of Urology, Semmelweis University, Üllői Street 78/b, H-1082 Budapest, Hungary.
Urachal cancer (UrC) is a rare disease which is mostly diagnosed late due to symptoms caused by its local invasion to the urinary bladder. Given the lack of clinical trials and guideline recommendations for systemic treatment, a molecularly informed precision oncology approach is a viable option for UrC already in the early lines of systemic treatment. While single case experiences may provide valuable reference for later decision-making, well-documented clinical experience with off-label targeted treatments is limited to a few patients.
View Article and Find Full Text PDFSurgical treatment of urachal adenocarcinoma with lung metastasis: A case report and literature review.
Thorac Cancer
December 2024
Department of Thoracic Surgery, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
Article Synopsis
- * Most urachal cancers are classified as intestinal adenocarcinomas (90%), and they often occur in the lower urachal tube or bladder dome, leading to late diagnoses due to the silent nature of early stages.
- * Treatment options for this aggressive cancer include surgery and chemotherapy (like cisplatin), with some patients showing positive responses to targeted therapies; a case study highlighted successful surgical treatment for a patient with advanced disease.
Urachal Carcinoma: Insights From a National Database.
Clin Genitourin Cancer
December 2024
Department of Urology, Rush University, Chicago, IL, USA. Electronic address:
Introduction: Urachal carcinoma (UrC) is a rare, nonurothelial malignancy, comprising less than 1% of all bladder cancers. It usually affects males in their fifth to sixth decade and is often diagnosed at an advanced stage with metastasis. This study examines UrC population characteristics and management.
View Article and Find Full Text PDFEfficacy of Keratin AE1/AE3 Staining in Evaluating Resection Margins of a Urachal Remnant and Improving Surgical Precision and Outcomes: A Case Report.
Cureus
June 2024
Department of Plastic and Aesthetic Surgery, Kitasato University School of Medicine, Sagamihara, JPN.
A urachal remnant is a rare condition characterized by the persistence of the urachus beyond birth, often presenting with symptoms such as umbilical effusion, periomphalitis, and abdominal pain. Surgical resection is the cornerstone of treatment, but ensuring complete removal of urachal epithelium at the resection margin remains a challenge. This case report focuses on evaluating resection margins of urachal remnants and reports the case of a 25-year-old woman with complaints of umbilical effusion and a mass.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!